Literature DB >> 9865812

P3a of event-related potential in chronic methamphetamine dependence.

A Iwanami1, N Kuroki, S Iritani, H Isono, Y Okajima, K Kamijima.   

Abstract

To investigate the psychophysiological features of methamphetamine (MAP) dependence, we recorded auditory event-related potentials (ERPs) in 15 patients with MAP dependence and in 15 age-matched normal controls. ERPs were recorded during a standard oddball task and a read task similar to those employed by Squires et al. (Squires NK, Squires KC, Hillyard SA [1975] Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. Electroenceph Clin Neurophysiol 38:387-401). The patients with MAP dependence showed reduced P3a amplitude and area in the read task and delayed P3b latency with normal P3b amplitude and area in the oddball task. These results suggest that central noradrenergic dysregulation may persist after the remission of acute psychotic symptoms in MAP psychosis and that chronic MAP dependence would produce impairment of the frontal cortex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865812     DOI: 10.1097/00005053-199812000-00002

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  3 in total

1.  Nicotine deprivation influences P300 markers of cognitive control.

Authors:  David E Evans; Nathan D Maxfield; Kate Janse Van Rensburg; Jason A Oliver; Kade G Jentink; David J Drobes
Journal:  Neuropsychopharmacology       Date:  2013-06-28       Impact factor: 7.853

Review 2.  EEG biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research.

Authors:  Tato M Sokhadze; Rex L Cannon; David L Trudeau
Journal:  Appl Psychophysiol Biofeedback       Date:  2008-01-24

Review 3.  The neurobiology of methamphetamine induced psychosis.

Authors:  Jennifer H Hsieh; Dan J Stein; Fleur M Howells
Journal:  Front Hum Neurosci       Date:  2014-07-22       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.